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Abstract
Patients with a history of diabetes mellitus (DM) have worse survival than those without DM after liver transplantation.
However, the effect of liver grafts from DM donors on the post-transplantation survival of recipients is unclear. Using the
Scientific Registry of Transplant Recipients database (2004–2008), 25,413 patients were assessed. Among them, 2,469
recipients received grafts from donors with DM. The demographics and outcome of patients were assessed. Patient survival
was assessed using Kaplan–Meier methodology and Cox regression analyses. Recipients from DM donors experienced worse
graft survival than recipients from non-DM donors (one-year survival: 81% versus 85%, and five-year survival: 67% versus
74%, P,0.001, respectively). Graft survival was significantly lower for recipients from DM donors with DM duration .5 years
(P,0.001) compared with those with DM duration ,5 years. Cox regression analyses showed that DM donors were
independently associated with worse graft survival (hazard ratio, 1.11; 95% confidence interval, 1.02–1.19). The effect of DM
donors was more pronounced on certain underlying liver diseases of recipients. Increases in the risk of graft loss were noted
among recipients from DM donors with hepatitis-C virus (HCV) infection, whereas those without HCV experienced similar
outcomes compared with recipients from non-DM donors. These data suggest that recipients from DM donors experience
significantly worse patient survival after liver transplantation. However, in patients without HCV infection, using DM donors
was not independently associated with worse post-transplantation graft survival. Matching these DM donors to recipients
without HCV may be safe.
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Introduction
The growing incidence of type-2 diabetes mellitus (DM)
worldwide is recognized as one of the greatest challenges to public
health [1]. In 2011, 366 million people worldwide had DM, and
this figure is expected to rise to 552 million by 2030 [2]. In general,
DM patients suffer worse health-related outcomes than non-DM
patients in many medical conditions, and this is also true among
liver transplantation (LT) patients [3].
LT is a well-recognized treatment for patients with end-stage
liver disease (ESLD) and/or hepatocellular carcinoma (HCC).
Ten-year survival of 59% and 83% for deceased donor and living
donor transplantation, respectively, has been recorded [4]. In
recipients, the role of DM as an independent risk factor for poor
survival after LT has been examined explicitly in several studies: a
higher mortality in DM patients than in non-DM patients has
been observed [3,5–7]. The use of post-transplantation immuno-
suppressive drugs and other DM-associated factors (e.g., poor
wound healing, impaired neutrophil function, obesity, microvas-
cular/macrovascular disease) may result in poor outcomes among
DM patients undergoing LT [8]. However, whether or not DM
donors have a negative influence on the outcomes of LT recipients
is not known. Only a few studies regarding the effect of DM
donors on survival have been carried out. Thus, the goal of the
present study was to determine if DM donors affected the
mortality of LT patients after the procedure.
Based on a national registry database in the USA, we assessed
the LT outcomes of patients who received DM donor grafts and
compared the results with those who received non-DM donor
grafts. We wanted to know whether we could use DM donors
safely for patients with ESLD.
Patients and Methods
Ethical Statement
The study protocol was approved by the Research Ethical
Committee of Zhejiang University (Zhejiang, China). Written
informed consent was obtained from all participants. The patient
records/information was anonymized and de-identified prior to
analysis in the database.
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e98104
Data sources
This study used data from the Scientific Registry of Transplant
Recipients (SRTR). The SRTR data system includes data on all
donor, wait-listed candidates, and transplant recipients in the US,
submitted by the members of the Organ Procurement and
Transplantation Network (OPTN), and has been described
elsewhere. The Health Resources and Services Administration
(HRSA), US Department of Health and Human Services provides
oversight to the activities of the OPTN and SRTR contractors [9].
Study cohort
All LT patients who received a first isolated LT between 1
January 2004 and 31 December 2008 were eligible for inclusion
into the study. Donors were considered to have DM if positive
responses to the variable ‘‘donor’s history of diabetes’’ or ‘‘donor’s
duration of diabetes’’ were recorded. Donors were considered to
be non-diabetic if negative responses were recorded for these
variables. Recipients for whom a donor history of DM was not
known were excluded from the study.
Potentially confounding factors for donors and recipients were
examined. Recipient characteristics were: age; sex; ethnicity;
history of DM; history of HCC; whether the patients was receiving
artificial ventilation; whether the patient was undergoing dialysis
in the week before orthotopic liver transplantation (OLT); model
for end-stage liver disease (MELD) score; serum levels of
creatinine; serum level of bilirubin; and cause of liver disease.
Causes of liver disease were categorized as: hepatitis B virus
(HBV); hepatitis C virus (HCV); alcohol; non-alcoholic steatohe-
patitis (NASH); autoimmune disease (autoimmune hepatitis,
primary biliary cirrhosis, primary sclerosing cholangitis); and
other causes. Patients classified with HCV in addition to another
diagnosis were included under a diagnosis of HCV. Patients who
had a diagnosis of HCC were included in the cohort under their
primary cause of liver disease.
Donor variables were: age; sex; ethnicity; history of hyperten-
sion; body mass index (BMI); donor risk index (DRI) [10];
donation after cardiac death (DCD) donor; warm ischemia time
(WIT); cold ischemia time (CIT); and cause of death.
Outcome measures
The main outcomes were patient survival and graft function.
Current status and time-to-outcome were included as outcome
measures. Patient follow-up was defined as the time from
transplantation until the date of death or last known follow-up.
The occurrence and date of death were obtained from data
reported by the transplantation centers, and were completed using
data from the US Social Security Administration and OPTN.
Statistical analyses
The study cohort was compared for baseline characteristics with
regard to recipients and donors. Statistical analyses were carried
out using the Student’s t-test for continuous variables, and the chi-
square test for categorical variables. Survival was assessed using
Kaplan–Meier curves and compared with log-rank tests. Cox
proportional hazard models were created for the time-to-survival
and time-to-graft loss to evaluate the potential predictors of the
outcome measures. Variables that were significantly different in
the baseline comparison as well as those clinically relevant even if
similar at baseline were included in the models. Results were
expressed as hazard ratios (HRs) with 95% confidence intervals
(CIs). The causes of graft loss and patient death were analyzed and
compared between cases and controls. Results are the mean 6
standard deviation (SD) unless indicated otherwise. A standard
alpha level of 0.05 was taken to indicate statistical significance. All
statistical tests were two-sided. Analyses were conducted using
SPSS ver15.0 (SPSS, Chicago, IL, USA).
Results
Out of the 26,645 patients who underwent a first isolated LT
during the study period, 25,413 met the inclusion criteria after the
exclusion of LTs from donors whose DM histories were not known
(n= 1232, 4.6%). Of these, 2469 (9.7%) had DM and 22,944
(90.3%) did not. For the cohorts of recipients with DM donors, the
mean duration of follow-up was 32 months. The mean duration of
follow-up of recipients with non-DM donors was 34 months.
Baseline characteristics
The baseline characteristics of recipients from DM donors
(n = 2469) and recipients from non-DM donors (n = 22944) are
listed in Table 1. DM-donor recipients were older (DM donor
54.069.6 years vs. non-DM donor 53.0610.0 years; P,0.001) but
they (in general) displayed fewer risk characteristics compared with
non-DM-donor recipients. They had lower MELD scores (DM
donor 2069 vs. non-DM donor 2169; P,0.001), were less likely
to be on artificial ventilation (DM donor 3.7% vs. non-DM donor
5.0%; P=0.004) and were less likely to be on dialysis 1 week
before LT (DM donor 5.8% vs. non-DM donor 8.6%; P,0.001).
There was, however, a greater proportion of HCC recipients in
the DM donor cohort (DM donor 25.6% vs. non-DM donor
23.6%; P=0.026), whereas the proportion of recipients with DM
donors was similar (DM donor 23.8% vs. non-DM donor 22.3%;
P=0.098). In addition, DM donors were associated with more
adverse factors of graft quality, such as donor age (DM donor
54.5612.9 years vs. non-DM donor 40.2617.2 years; P,0.001),
history of hypertension (DM donor 78.3% vs. non-DM donor
28.2%; P,0.001), BMI (DM donor 3067 years vs. non-DM donor
2666 years; P,0.001), DRI (DM donor 2.0360.42 vs. non-DM
donor 1.7960.42; P,0.001), and CIT (DM donor 7.663.6 h vs.
non-DM donor 7.463.5 h; P,0.001). The mean WIT for DM
donor transplantation was 42.5618.8 min, while that of non-DM
donors was 41.6618.9 min (P=0.083). However, DM donor
transplantation was associated with a lower prevalence of non-
heart-beating donation (NHBD) (DM donor 3.7% vs. non-DM
donor 5.0%; P=0.003).
Overall graft survival
A total of 859 (34.8%) recipients from DM donors and 6,382
(27.8%) recipients from non-DM donors lost their grafts. At 1, 5
and 10 years, graft survival was 85%, 74% and 65%, respectively,
for recipients from non-DM donors, and 81%, 67% and 56%,
respectively, for recipients from DM donors (log rank P,0.001)
(Fig. 1A).
Data for the duration of DM were available for 2,199 of the
2,469 (89%) donors for whom DM history was known, of whom
1,251 (50.7%) were reported to have durations of DM .5 years.
Univariate analyses showed the lowest survival in this category (log
rank P,0.001) (Fig. 1B).
Predictors of graft loss at multivariate analyses
Initially, all variables were included in the multivariate analyses,
which comprised recipient characteristics (age, sex, ethnicity, cause
of liver disease, MELD score, HCC, being on artificial ventilation
at the time of LT, dialysis 1 week before LT); and donor
characteristics (age, DRI, DCD, history of hypertension).
Table 2 shows the factors identified as significant predictors of
graft loss in the entire study cohort using a Cox regression hazard
Liver Transplantation from Donors with Diabetes
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model. DM donors were associated with an increased risk of
mortality for patients after LT (HR =1.11; 95% CI = 1.02–1.19).
This increased risk of death for recipients from DM donors was
comparable in magnitude to other well-known independent risk
predictors of graft loss such as MELD at LT (HR =1.01 per unit),
recipient with HCC (HR =1.34), and DRI (HR =1.41 per unit).
Table 1. Comparison of patients who underwent transplantation using liver grafts from diabetes mellitus (DM) donors and those
who underwent transplantation using liver grafts from non-DM donors with respect to the baseline characteristics of recipients
and donors.
Recipient characteristic DM donors (n=2469) Non-DM donors (n =22944) P
Age (years) 54.069.6 53.0610.0 ,0.001
Male 1725 (69.9) 15,487 (67.5) 0.018
Ethnicity
White 1799 (72.9) 16,569 (72.2) 0.507
Black 236 (9.6) 2084 (9.1) 0.441
Asian 112 (4.5) 1086 (4.7) 0.686
Hispanic 298 (12.1) 2987 (13.0) 0.186
Other 24 (0.9) 218 (1.0) 0.925
DM 587 (23.8) 5118 (22.3) 0.098
HCC 633 (25.6) 5418 (23.6) 0.026
Cause of liver disease
HCV 1119 (45.3) 10,459 (45.6) 0.815
HBV 120 (4.9) 1157 (5.0) 0.730
NASH 152 (6.2) 1237 (5.4) 0.111
Alcohol 391 (15.8) 3255 (14.2) 0.027
Autoimmune disease 248 (10.0) 2465 (10.7) 0.304
Other 439 (17.8) 4371 (19.1) 0.131
Serum creatinine (mg/dL) 1.4361.21 1.5461.35 ,0.001
Serum bilirubin (mg/dL) 7.0669.78 7.77610.27 ,0.001
On artificial ventilation 92 (3.7) 1154 (5.0) 0.004
Dialysis within 1 week 142 (5.8) 1962 (8.6) ,0.001
MELD score 2069 2169 ,0.001
Donor characteristic DM donors (n=2469) Non-DM donors (n =22,944) P
Age (years) 54.5612.9 40.2617.2 ,0.001
Male 1375 (55.7) 13,810 (60.2) ,0.001
Ethnicity
White 1457 (59.0) 15,852 (69.1) ,0.001
Black 558 (22.6) 3433 (15.0) ,0.001
Asian 72 (2.9) 490 (2.1) 0.012
Hispanic 361 (14.6) 2964 (12.9) 0.018
Other 21 (0.8) 205 (0.9) 0.899
BMI (kg/m2) 3067 2666 ,0.001
Hypertension 1933(78.3) 6478(28.2) ,0.001
Cause of death
Anoxia 523 (21.1) 3338 (14.5) ,0.001
Cerebrovascular accident 1573 (63.7) 9460 (41.2) ,0.001
Head trauma 324(13.1) 9559 (41.7) ,0.001
Other 49 (2.1) 587 (2.6) 0.093
NHBD 91 (3.7) 1156 (5.0) 0.003
DRI 2.0360.42 1.7960.42 ,0.001
WIT (min) 42.5618.8 41.6618.9 0.083
CIT (h) 7.663.6 7.463.5 ,0.001
DM: diabetes mellitus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HBV: hepatitis B virus; NASH: non-alcoholic steatohepatitis; BMI: body mass index; NHBD:
non-heart-beating donor; DRI: donor risk index; WIT: warm ischemia time; CIT: cold ischemia time.
doi:10.1371/journal.pone.0098104.t001
Liver Transplantation from Donors with Diabetes
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e98104
These data showed that a liver graft donated from a subject with
DM was an independent risk predictor of graft loss.
Graft survival as related to allocation of DM donors
A liver graft donated from a subject with DM was an
independent risk predictor of graft loss, so we explored the effect
of DM/non-DM donors on graft survival in relation to the
underlying disease of recipients (Table 1). Graft survival from DM
donors was worse in recipients with HCV infection, alcoholic liver
disease and other liver diseases (Fig. 2A, P,0.001; and Fig. 2C,
P=0.014; respectively). However, the differences between DM
and non-DM donors on graft survival disappeared in recipients
with HBV infection, NASH and autoimmune liver disease (Fig. 2B,
P=0.613; Fig. 2D, P=0.742; Fig. 2E, P=0.060; and Fig. 2F,
P=0.074; respectively).
The impact of receiving a liver graft from a subject with DM on
graft survival in relation to the underlying disease was investigated
further in multivariate analyses. To better understand the effects of
DM donors on the various diagnoses studied, we plotted the HR
(95% CIs) found in the groups. Only in recipients with HCV was
donation from a DM patient an independent predictor of graft loss
(Fig. 3).
Discussion
Using comprehensive clinical data from the SRTR database,
the results of the present study suggested that receiving a liver graft
from a subject with DM was associated with an increased
prevalence of graft loss in a cohort of patients undergoing LT.
This increased risk of death remained significant after adjustment
for factors for donors and recipients, including those that might
represent a selection bias, such as the prevalence of HCC and
HCV. Moreover, the present study showed that survival differ-
ences were primarily because of lower survival in patients who
received liver grafts from donors with a longer duration of DM. If
we were to assume that longer duration of DM is a surrogate
marker of DM severity, our findings suggest that LT patients who
receive liver grafts from subjects with more severe DM may have
poorer outcomes. This notion suggests that donors with DM
should be employed with caution. This is the first study to
compare the outcome of LT recipients from DM donors and non-
DM donors.
Even though recipients from DM donors experienced signifi-
cantly worse graft survival after transplantation compared with
those of non-DM donors, a favorable outcome could be expected
if a DM donor is transplanted in a favorable condition. Increased
risks associated with transplantation for recipients with HCV,
HCC or high MELD score have been accepted to extend
transplantation to greater numbers of patients in need. We
demonstrated that the increased risk of graft loss associated with
Figure 1. Kaplan–Meier survival curves comparing overall graft
survival and graft survival stratified by donor duration of
diabetes mellitus (DM) history in recipients from DM and non-
DM donors. A) Overall graft survival in recipients from DM and non-
DM donors. Recipients with DM donors had significantly lower survival.
(B) Graft survival by the duration of DM in the donor. Recipients of liver
grafts from DM donors with durations of DM .5 years had significantly
lower survival compared with those with durations of DM ,5 years and
recipients from non-DM donors. Continuous line depicts recipients from
DM donors and dashed line depicts recipients from non-DM donors.
doi:10.1371/journal.pone.0098104.g001
Table 2. Cox proportional hazard regression analyses to assess predictors of survival of grafts and patients.
Variable Univariate Multivariate
HR 95% CI HR 95% CI
DM donors (ref: non-DM donors) 1.24 1.18–1.36 1.11 1.02–1.19
MELD score 1.01 1.01–1.01 1.01 1.01–1.02
HCC (ref: no HCC) 1.15 1.10–1.21 1.34 1.25–1.44
DRI 1.70 1.61–1.79 1.44 1.33–1.57
DM: diabetes mellitus; MELD: Model for End-Stage Liver Disease; HCC: hepatocellular carcinoma; DRI: donor risk index.
doi:10.1371/journal.pone.0098104.t002
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LT from DM donors was very comparable with the risks
associated with these other, well-accepted predictors of risk.
Furthermore, by considering the interactions between these risks, a
more precise understanding of the impact of receiving a liver graft
from a DM donor can be achieved. Increases in the risk of graft
loss were noted among recipients from DM donors with HCV at
the time of LT, whereas those without HCV experienced greatly
improved outcomes (even comparable with recipients from non-
DM donors with the same underlying liver disease). In patients
without HCV infection before LT, using DM donors was not
independently associated with worse graft survival post-transplan-
tation. Therefore, matching DM donors to recipients without
HCV may be safe.
Several studies have noted that patients with a history of DM
are associated with significant morbidity and mortality post-OLT
[3,6,11,12]. However, few studies have addressed the impact on
LT outcomes of receiving a liver graft from a donor with DM.
Several studies have associated DM with hepatic steatosis, which is
a benign form of non-alcoholic fatty liver disease (NAFLD) [13].
Increasing evidence suggests that NAFLD patients with DM are
more likely to progress to NASH than NAFLD patients without
DM [14,15]. NASH is a damaging form of NAFLD that leads to
fibrosis and cirrhosis, resulting in poor graft function [16]. Studies
have shown that grafts with moderate hepatic steatosis (.30%)
accelerate the progression of HCV-based disease, and should not
be used for HCV patients with high MELD scores [17]. Another
study found that moderate steatosis in combination with prolonged
ischemic time resulted in worse transplantation outcomes in
recipients with HCV [18]. The association of worse graft outcomes
in HCV-positive recipients with liver grafts from donors with DM
seen in the present study may be attributable to pre-existing graft
Figure 2. Kaplan–Meier survival curves comparing graft survival of recipients from diabetes mellitus (DM) and non-DM donors
according to underlying liver disease. A) HCV, (B) HBV, (C) alcoholic liver disease, (D) NASH, (E) autoimmune liver disease, and (F) other liver
disease. Graft survival was significantly lower in recipients from DM donors with HCV infection and alcoholic liver disease. Graft survival was similar
between recipients from DM and non-DM donors with HBV infection, NASH, autoimmune liver disease and other liver disease. Continuous line
depicts recipients from DM donors and dashed line depicts recipients from non-DM donors.
doi:10.1371/journal.pone.0098104.g002
Figure 3. Hazard ratios (with 95% CI) to compare the risk of
graft loss after liver transplantation in recipients from diabetes
mellitus (DM) donors with various types of underlying liver
diseases.
doi:10.1371/journal.pone.0098104.g003
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steatosis and fibrosis induced by DM in the donor, which is further
exacerbated by post-transplantation HCV recurrence with subse-
quent fibrosis.
The number of patients waiting for organ transplantation
continues to grow, but donor organs remain in short supply. Over
the past few years, steps have been taken to increase the number of
organs available for OLT, including using split-LT and introduc-
ing living donor LT programs. Marginal donor grafts have also
been explored thanks to improvements in surgical methods and
immunosuppression. These marginal donors include those with
steatotic livers, who are elderly, DCD donors, and donors infected
with HCV [19,20]. Utilization of poorer-quality organs is in
response to the increasing divergence between the supply and
demand of organs. Improved understanding of the combined risks
associated with different factors between donors and recipients is
vital to decisions regarding utilization. Transplantation policy
should incorporate adequate risk adjustment into measurement of
the performance of transplantation centers and into improving
informed consent to maximize the individual and societal benefits
associated with transplantation.
Due to the registry-based nature of the present study, it had
limitations that were mainly related to the data. The most
important limitation was the inability to assess steatosis or fibrosis
because donor biopsies were not carried out routinely. Secondly,
any large database is subject to reporting bias, errors in data entry,
and inaccuracies. The SRTR database is not immune to this
problem, but these issues may be less of a concern in studies using
the SRTR database because of the mandatory participation of all
transplantation centers and the electronic editing system, which
minimizes data-entry errors. Thirdly, the lack of information on
previous and present use of anti-DM drugs as well as liver-biopsy
details limited our ability to generalize the results.
The present study also had several extremely important
strengths. We included the largest population of patients who
have received DM liver grafts with the longest follow-up times
available based on the SRTR database (which represents the
entire transplantation population in the USA). The large sample
size allowed more robust conclusions to be drawn in comparison
with previous case reports with smaller sample sizes. Moreover,
this is the first survival analysis study concerning post-transplan-
tation graft survival of recipients who received liver grafts from
subjects with DM. The SRTR database collects detailed pre-
transplantation variables that are known predictors of post-
transplantation survival and adjusts for these variables to provide
a less confounded assessment of the true effect of receiving a liver
graft from a subject with DM on post-transplantation outcome.
The limitations mentioned above affected our ability to confirm
the reasons underlying our findings, but they did not affect the
validity of our primary analyses of the survival of patients and
grafts.
In summary, using the largest dataset available for analyses and
the longest follow-up periods available to date, we showed that
graft survival in recipients with grafts from subjects with DM were
worse than those with non-DM grafts when other predictors of
post-transplantation survival were taken into account. However,
allocating these DM donors to patients without HCV could also
result in similar post-transplantation outcomes with non-DM
donors. With careful implementation and informed consent from
the recipients, matching these DM donors to recipients without
HCV may be safe.
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